Century Therapeutics Re-prioritizes Pipeline for Key Programs

Century Therapeutics ( (IPSC) ) just unveiled an update.

Century Therapeutics announced a strategic re-prioritization of its pipeline to focus on four transformative programs, particularly CNTY-308 and CNTY-101, aimed at B-cell mediated autoimmune diseases and malignancies. The company reported a strong cash position, extending its runway into the fourth quarter of 2026, and highlighted its decision to discontinue the ELiPSE-1 trial due to unmet transformational thresholds in late-stage R/R NHL, while emphasizing the potential of CNTY-101 in autoimmune diseases.

More about Century Therapeutics

Century Therapeutics is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer.

YTD Price Performance: -43.46%

Average Trading Volume: 477,732

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $50.01M

Learn more about IPSC stock on TipRanks’ Stock Analysis page.